GOSWAMI JOYDEEP 4

What Happened

• Joydeep Goswami, a director of BioLife Solutions, received an award of 8,170 restricted shares on 2026-02-24 (transaction code A — grant/award). The filing lists no purchase price or fair-market value (N/A), indicating this was a compensation grant rather than an open-market purchase.

Key Details

• Transaction date: 2026-02-24 (Form 4 filed 2026-02-26 — timely within the usual two-business-day window).
• Transaction type/code: A = Award/Grant (restricted stock).
• Shares granted: 8,170; price reported as N/A (no cash purchase).
• Vesting: Per footnote, granted under the BioLife Solutions 2023 Performance Incentive Plan and fully vests on the first anniversary of the vesting date of January 2, 2026 (i.e., fully vested on/around January 2, 2027).
• Shares owned after transaction: Not specified in the provided filing excerpt.
• No tax-withholding, 10b5-1 plan, or sale information reported in this transaction.

Context

• This is a compensation-related restricted stock grant, common for executives/directors as part of pay or retention and not an active market buy or sell. Such awards do not by themselves signal a buy or sell intent; their primary purpose is typically compensation or retention.